In patients predisposed to develop sJIA-LD, biologic drugs could promote CD4+ cell differentiation into Th1 cells rather than Th17 cells (induced by high levels of IL-1 and IL-6 usually found in sJIA), with a consequent increase in IFNγ production [24]. The gene discussed is CD4; the disease is systemic-onset juvenile idiopathic arthritis.